10-12 September 2018 //  Lancaster Royal Hotel, London



TCR2 Therapeutics, Associate Sponsor at Cell & Gene Therapy Europe

TCR2 Therapeutics is pioneering a novel class of T cell therapies that utilize the full signaling power of TCR to eliminate solid tumors. Its TRuC™ platform has demonstrated superior preclinical activity compared to CAR-T. TCR2 was founded by Patrick Baeuerle and MPM Capital in 2015 with a $44.5M Series A.

2017 Speakers

"It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance."

Bertrand Alexandre, Director, Marketing Europe, Celyad